• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

"The global market for new cancer patients is set to increase from 4.0 million cases in the major cancer markets in 2007 to 4.2 million in 2012"

The global cancer market has seen a continued period of rapid growth. Global sales for cancer-treating drugs increased by 13.3% in 2007, primarily driven by growth in sales of innovative drugs. Although growth rates for this market will slow due to generic competition, the market is predicted to expand to $103.9 billion by 2012, equivalent to CAGR of 9.4%.

Key findings from this report:

• The global cancer market grew to US$66.2 billion in 2007, a year-on-year increase of 13.3%.
• This market growth in 2007 was primarily driven by growth of 44.0% in innovatives sales.
• There were a total of 21 different cancer therapies generating global sales in excess of US$1 billion in 2007.
  
• The leading company by cancer sales in 2007 was Amgen, with sales of US$11.1 billion.
• The global cancer market is forecast to expand to US$103.9 billion in 2012, equivalent to a CAGR of 9.4% over the next 5 years.
  

This comprehensive report delivers market forecasts and overviews to help inform your pharmaceutical business decision-making.

Features of the report:

• Sales forecast for top ten companies providing cancer treatment medicines.
• Analysis of leading cancer products likely to loose patent protection in the next ten years.
• Sales forecasts to 2012 for the top ten cancer medicines and forecasts by drug class.
• Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
• Breakdown of the major market trends and business opportunities

Use This Report To:

•  Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.

•  Identify potential areas of pharmaceutical market growth and opportunities for delivering successful sales growth

• Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.

The 122 page publication contains 49 Figures and 43 Tables to help you make sense of the wealth of data. This unique report from URCH Publishing will be of particular use to those involved in:
- corporate planning,
- sales and marketing,
- portfolio management, and,
- market forecasting.

Cancer Market Trends 2008 - 2012 is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. The final report chapter outlines future cancer market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cancer market trends.

Summary
Introduction
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

Chapter 1 Introduction
Global cancer market
Report overview
Chapter 2 Key disease markets
Key cancer markets
Cancer epidemiology
Cancer treatment-related disorders
Nausea and vomiting
Hematological disorders
Other cancer treatment side effects

Chapter 3 Key drug classes
Key drug classifications
Hormonals drug class
Chemotherapeutics drug class
Innovatives drug class
Selected adjuncts drug class

Chapter 4 Key products
Leading products
Top 10 leading cancer drugs

 

Chapter 5 Key companies
Major cancer players
Leading companies

 

Chapter 6 Key trends and opportunities
Key disease market forecasts

Key drug class forecasts
Key product forecasts
Key company forecasts
Appendix
Proprietary data sources

List of Figures (Cancer Market Trends 2008 - 2012)

Figure 1: Global cancer market, 2003-2007
Figure 2: Report structure
Figure 3: Disease burden in seven major pharmaceutical markets, 2007
Figure 4: New cancer cases in the US, 2008
Figure 5: Cancer deaths in the US, 2008
Figure 6: Cancer epidemiology in seven major markets, 2007
Figure 7: Prostate cancer epidemiology in seven major markets, 2007
Figure 8: Breast cancer epidemiology in seven major markets, 2007
Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2007
Figure 10: Colorectal cancer epidemiology in seven major markets, 2007
Figure 11: Urinary bladder cancer epidemiology in seven major markets, 2007
Figure 12: Non-Hodgkin's lymphoma epidemiology in seven major markets, 2007
Figure 13: Melanoma epidemiology in seven major markets, 2007
Figure 14: Kidney and renal pelvis cancer epidemiology in seven major markets, 2007
Figure 15: Leukemia epidemiology in seven major markets, 2007
Figure 16: Uterine corpus/endometrium (uterus) cancer epidemiology in seven major markets, 2007
Figure 17: Global cancer market by drug class, 2007
Figure 18: Global cancer market by drug class, 2003-2007
Figure 19: Global cancer market trends by drug class, 2006-2007
Figure 20: Hormonals market, 2003-2007
Figure 21: Leading hormonal drugs by approval date, 1985-2007
Figure 22: Chemotherapeutics market, 2003-2007
Figure 23: Leading chemotherapeutic drugs by approval date, 1991-2007
Figure 24: Innovatives market, 2003-2007
Figure 25: Leading innovative drugs by approval date, 1983-2007
Figure 26: Selected adjuncts market, 2003-2007
Figure 27: Leading selected adjunct drugs by approval date, 1988-2007
Figure 28: Cancer blockbuster trends, 2006-2007
Figure 29: Top 10 cancer products by global sales, 2007
Figure 30: Top 10 companies by global cancer sales, 2007
Figure 31: Top 10 companies by global cancer market share, 2007
Figure 32: Top 10 companies by global cancer sales, 2006-2007
Figure 33: Cancer incidence forecasts by geographic market, 2007-2012
Figure 34: Cancer incidence forecasts by disease market, 2007-2012
Figure 35: Global cancer market forecast, 2003-2012
Figure 36: Global cancer market forecasts by drug class, 2003-2012
Figure 37: Top 10 cancer drugs by forecast sales, 2012
Figure 38: Rituxan/MabThera (rituximab) forecast sales, 2003-2012
Figure 39: Herceptin (trastuzumab) forecast sales, 2003-2012
Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2012
Figure 41: Avastin (bevacizumab) forecast sales, 2004-2012
Figure 42: Gleevec/Glivec (imatinib) forecast sales, 2003-2012
Figure 43: Neulasta (pegfilgrastim) forecast sales, 2003-2012
Figure 44: Eprex/Procrit (epoetin alfa) forecast sales, 2003-2012
Figure 45: Taxotere (docetaxel) forecast sales, 2003-2012
Figure 46: Epogen (epoetin alfa) forecast sales, 2003-2012
Figure 47: Eloxatin (oxaliplatin) forecast sales, 2003-2012
Figure 48: Forecast patent expiries by 2007 global sales, 2008-2017
Figure 49: Top ten companies by cancer sales trends, 2007-2012

List of Tables (Caner Market Trends 2008 -2012

Table 1: Global cancer market trends by drug class, 2005-2007
Table 2: Leading hormonal drugs, 2007
Table 3: Hormonals market trends, 2005-2007
Table 4: Leading chemotherapeutic drugs, 2007
Table 5: Chemotherapeutics market trends, 2005-2007
Table 6: Leading innovative drugs, 2007
Table 7: Innovatives market trends, 2005-2007
Table 8: Leading selected adjunct drugs, 2007
Table 9: Selected adjuncts market trends, 2005-2007
Table 10: Top 20 cancer products by global sales, 2005-2007
Table 11: Rituxan/MabThera (rituximab) profile, 2007
Table 12: Herceptin (trastuzumab) profile, 2007
Table 13: Aranesp (darbepoetin) profile, 2007
Table 14: Avastin (bevacizumab) profile, 2007
Table 15: Gleevec/Glivec (imatinib) profile, 2007
Table 16: Neulasta (pegfilgrastim) profile, 2007
Table 17: Eprex/Procrit (epoetin alfa) profile, 2007
Table 18: Taxotere (docetaxel) profile, 2007
Table 19: Epogen (epoetin alfa) profile, 2007
Table 20: Eloxatin (oxaliplatin) profile, 2007
Table 21: Top 10 companies by global cancer sales, 2005-2007
Table 22: Amgen profile, 2007
Table 23: Amgen cancer pipeline, 2007
Table 24: Roche profile, 2007
Table 25: Roche cancer pipeline, 2007
Table 26: Novartis profile, 2007
Table 27: Novartis cancer pipeline, 2007
Table 28: Genentech profile, 2007
Table 29: Genentech cancer pipeline, 2007
Table 30: Sanofi-Aventis profile, 2007
Table 31: Sanofi-Aventis cancer pipeline, 2007
Table 32: AstraZeneca profile, 2007
Table 33: AstraZeneca cancer pipeline, 2007
Table 34: Johnson & Johnson profile, 2006
Table 35: Johnson & Johnson cancer pipeline, 2007
Table 36: Pfizer profile, 2007
Table 37: Pfizer cancer pipeline, 2007
Table 38: Eli Lilly profile, 2007
Table 39: Eli Lilly cancer pipeline, 2007
Table 40: Merck profile, 2007
Table 41: Merck cancer pipeline, 2007
Table 42: Global cancer market forecasts by drug class, 2005-2012
Table 43: Top 10 cancer drugs forecasts, 2005-2012
Table 44: Top 10 companies by cancer sales forecasts, 2007-2012
Table 45: Top 56 cancer products by global pharmaceutical sales, 2005-2007
Table 46: Top 14 companies by global cancer sales, 2005-2007

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School.